ElixaMD Review
Semaglutide GLP-1 weight-loss telehealth · Independently scored 6.3/10
Best for: seeing what it charges before you answer any medical questions
ElixaMD's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
The $179 first-month figure for compounded semaglutide injections is an intro rate. No membership, no contract and no insurance are involved, and delivery costs nothing. Everything else folds in: a patient portal, 24/7 support, care coaching, dietician visits at no charge and 1:1 physician guidance. HSA/FSA money qualifies. ElixaMD does something rare and names its compounders, RedRock and Beaker, alongside a full legal suite, and it discloses that compounded drugs are not FDA-approved. Semaglutide is the only molecule advertised, and no verifiable LegitScript seal is displayed.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to ElixaMD
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
ElixaMD at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide
- Starting price
- $179/mo ('$179 first month' intro/sale, no contract; ongoing/higher-dose tiers ~$249-$299; HSA/FSA eligible)
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How ElixaMD scores
Six columns, each one computed from something ElixaMD has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
8.5/10Dispenses semaglutide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on ElixaMD
Last checked June 2026- Re-read the price on file across 1 dose or plan tier
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with ElixaMD involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1ElixaMD publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3ElixaMD does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- No state list is published, so whether ElixaMD serves your state cannot be confirmed from its site.
ElixaMD support, as documented
- Phone
- (303) 563-7471
- help@elixamd.com
GLP-1 medications ElixaMD offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
'$179 first month' intro/sale, no contract; ongoing/higher-dose tiers ~$249-$299; HSA/FSA eligible
Check the price yourself before you pay
Every figure here was read off ElixaMD's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What ElixaMD charges
The standing price at ElixaMD is $179/month.
- Compounded semaglutide — $179/month
The median across the GLP-1 providers we track is about $169/month, so this lands mid-market — close enough that the deciding factor is unlikely to be price.
Found dispenses semaglutide from $149/month, which makes it the honest comparison to run before committing here.
What ElixaMD dispenses
ElixaMD prescribes semaglutide (approved as Wegovy and Ozempic). Between them these are among the best-evidenced options in this class. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.
What we could verify
ElixaMD publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
Our read
ElixaMD lands mid-market on price without a standout advantage or an obvious problem. It comes down to whether its particular package fits. Breeze Meds is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
ElixaMD's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay ElixaMD
Starting at $179/month. Check today's price, then book the free consultation.
Where ElixaMD is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this ElixaMD review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See ElixaMD's current pricing
Plans start at $179/month. The free consultation is where you learn whether you qualify, and what it costs today.